AKRO - Akero Therapeutics, Inc.

54.65
0.100   0.183%

Share volume: 15,312,254
Last Updated: 12-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 3.72%

PREVIOUS CLOSE
CHG
CHG%
$54.55
0.10
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
37%
Profitability 35%
Dept financing 19%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0.18%
6 Months
22.20%
1 Year
21.09%
2 Year
79.06%
Key data
Stock price
$54.65
P/E Ratio 
0.00
DAY RANGE
$54.37 - $54.82
EPS 
-$3.74
52 WEEK RANGE
$31.80 - $57.35
52 WEEK CHANGE
$25.14
MARKET CAP 
3.798 B
YIELD 
N/A
SHARES OUTSTANDING 
82.316 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-08-2025
BETA 
0.14
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Andrew Cheng
Region: US
Website: akerotx.com
Employees: 30
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Akero Therapeutics, Inc. engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins.

Recent news